48 results about "Platelet activation" patented technology

An implantable pump system is provided, including an implantable blood pump suitable for use as a partial support assist device, the system further including an extracorporeal battery and a controller coupled to the implantable pump, and a programmer selectively periodically coupled to the controller to configure and adjust operating parameters of the implantable pump. The implantable pump includes a flexible membrane coupled to an electromagnetic actuator including a magnetic assembly and electromagnetic assembly, so that when the electromagnetic assembly is energized, the electromagnetic assembly causes wavelike undulations to propagate along the flexible membrane to propel blood through the implantable pump. The controller may be programmed by a programmer to operate at frequencies and duty cycles that mimic physiologic flow rates and pulsatility while operating in an efficient manner that avoids thrombus formation, hemolysis and / or platelet activation.

This invention discloses a method for preparing a composite spray that improves hemostasis at wound sites. The composite spray includes solution A and solution B, where solution B is an aqueous solution of sodium alginate. The preparation method of solution A includes: 1. Dissolving a lipopeptide conjugate, cholesterol, distearylphosphatidylcholine, distearylphosphatidylserine, and dimethyl sulfoxide in a chloroform-methanol mixed solution to obtain a mixed system; 2. Preparing a precursor solution from the mixed system using a thin-film hydration method; 3. Adding calcium chloride to the precursor solution and reacting it in the dark to obtain solution A. This invention designs the precursor solution based on the function of natural platelets, and its function is equivalent to that of nanoplatelets. Combined with sodium alginate, it can specifically alleviate the adverse effects on the coagulation system caused by blood loss, such as fibrin degradation and reduced platelet activation, at wound sites. It has the characteristics of rapid hemostasis, good bioactivity, and rapid wound healing.

The utility model discloses a hemostasis assist device for vascular surgery, which relates to the technical field of medical instruments, and comprises a fixing mechanism, a vascular surgery hemostasis mechanism is arranged in the fixing mechanism, the vascular surgery hemostasis mechanism comprises a knob, and the bottom of the knob is fixedly connected with a threaded column. According to the hemostasis mechanism for the vascular surgery department, during hemostasis, the periphery of a wound can be heated through the heating block across the replacement pad, the temperature of the periphery of the wound reaches 37-42 DEG C, activation of platelets can be accelerated to a certain extent at the temperature, energy metabolism of the platelets is accelerated within the temperature range, and the blood circulation is accelerated. The increase of the concentration of calcium ions in the blood platelets is an important signal of platelet activation, and the increased concentration of the calcium ions can promote the activation of glycoprotein receptors on platelet membranes, so that the binding capacity of the blood platelets and fibrinogen is enhanced, the aggregation of the blood platelets is accelerated, and the hemostasis speed is accelerated.

Synthetic hemocompatible vascular grafts manufactured from polyvinyl alcohol-based biomaterials containing crystalline segments of polyvinyl alcohol, which are long-term fully functioning vascular grafts that provide no activity towards immune systems in recognizing surfaces as foreign bodies that would normally lead to fibrosis, platelet activation and subsequent thrombi formation, and thus occlusion of the grafts.

The application discloses a multifunctional blood vessel stent with a negative Poisson's ratio structure and a preparation method thereof, relates to the technical field of medical devices, and comprises the construction of a blood vessel stent model with a negative Poisson's ratio structure, selective laser melting additive manufacturing, chemical polishing treatment and surface biomimetic modification treatment. The stent can better adapt to the deformation of a blood vessel by virtue of the negative Poisson's ratio characteristic, reduces incompatibility caused by different deformation steps, the structure of the stent is round and smooth, blood flow turbulence and vortex at sharp corners of a traditional stent can be effectively avoided, the hemodynamic performance is improved, the risk of platelet activation and thrombosis is reduced, a surface gradient coating is prepared, multi-mechanism synergy is realized, and the formation of an endothelial layer on the surface of the stent is facilitated.

Methods of inhibiting platelet activation and aggregation using peptide vaccines having binding specificity for the α subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis without causing bleeding.

The invention discloses application of a marker to preparation of a kit for diagnosing chronic obstructive pulmonary diseases. According to the application disclosed by the invention, the accuracy of diagnosing the chronic obstructive pulmonary disease by using (R)-3-hydroxytetradecanoic acid alone or in combination with the azelayl platelet activating factor is relatively high; on the basis of combination of (R)-3-hydroxytetradecanoic acid and an azelayl platelet activating factor, the compound is prepared. The compound can be further combined with one or two of 1-hexadecyl-2-(5-oxovaleryl)-sn-glycerol-3-phosphorylcholine, 1-O-hexadecyl-SN-glycerol-3-choline phosphoric acid, lauroyl-L-carnitine and beta-acetyl-gamma-O-alkyl-L-alpha-phosphatidylcholine to be used for diagnosing the chronic obstructive pulmonary disease. Therefore, a diagnostic kit for diagnosing the chronic obstructive pulmonary disease can be prepared on the basis of the scheme, and the kit contains a compound standard substance corresponding to the scheme and can also contain an internal standard compound for mass spectrum quantitative analysis.

The invention belongs to the technical field of biological medicine, and relates to an anticoagulant, in particular to an anticoagulant for a high-precision animal blood cell analyzer and application of the anticoagulant in leukocyte classification. The anticoagulant comprises a buffer and anticoagulation matrix component and an active component, wherein in every 100 mL of the anticoagulant, the buffer and anticoagulation matrix component formula comprises 1.5 to 2 g of citrate, 0.3 to 0.5 g of citric acid and 0.15 to 0.20 g of EDTA-K2 (Ethylene Diamine Tetraacetic Acid), and the active components comprise 0.08 to 0.10 g of low molecular weight enzymolysis carboxymethyl chitosan, 1.0 to 1.2 g of hydroxypropyl-beta-cyclodextrin, 10 to 15 mg of dipyridamole and 8 to 10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and leukocyte morphological deformation, realizes accurate identification in leukocyte five-classification, has a classification accuracy rate of 98%, and is suitable for veterinary clinical hematology examination and animal epidemic disease monitoring.

The invention discloses a macrophage-platelet targeting delivery system carrying genes and mitochondria as well as a preparation method and application of the macrophage-platelet targeting delivery system. The platelet loaded with the PPAR gamma gene nano-composite is covalently linked to the surface of macrophage through a click chemical reaction, and a novel cell composite carrier is constructed. According to the system, the natural chemotaxis of macrophages to an injured part is fully utilized to realize precise targeting, and PPAR gamma genes and functional mitochondria are synchronously released through platelet activation in an injured microenvironment, so that the energy metabolism and lipid homeostasis of the macrophages are cooperatively regulated and controlled, the cellular burial function of the macrophages is effectively recovered, and tissue repair and regeneration are promoted. Experimental results show that the delivery system is reliable in preparation method and high in targeting efficiency, axon regeneration, myelin sheath repair and motor function recovery can be remarkably promoted in a spinal cord injury model, and a brand-new synergistic treatment strategy is provided for tissue injury repair.

The invention relates to the technical field of medicines, in particular to application of benzbromarone in preparation of antithrombotic drugs. The research finds that benzbromarone clinically used for treating hyperuricemia can be combined with HSP47 on platelets to inhibit the interaction between the HSP47 and collagen so as to reduce platelet activation and thrombosis, which prompts that benzbromarone is an HSP47 inhibitor with an anti-platelet effect; benzbromarone has the effects of inhibiting mouse common carotid artery thrombosis and relieving cerebral ischemia reperfusion injury. Experiments finally confirm that benzbromarone can inhibit formation of common carotid artery thrombosis, does not affect the blood coagulation function, is low in cytotoxicity, has the drug effect similar to that of aspirin and clopidogrel which are commonly used at present, and can become an effective and safe therapeutic drug for cerebral arterial thrombosis.

The application belongs to the technical field of biological medicine, and relates to an anticoagulant and application thereof in white blood cell classification for high-precision animal blood cell analyzers. The anticoagulant comprises two parts of buffer and anticoagulant matrix components and active components. In the anticoagulant, the buffer and anticoagulant matrix component formula comprises 1.5-2 g of citrate, 0.3-0.5 g of citric acid and 0.15-0.20 g of EDTA-K2 per 100 mL of the anticoagulant, and the active component comprises 0.08-0.10 g of low-molecular enzymatic hydrolysis carboxymethyl chitosan, 1.0-1.2 g of hydroxypropyl-beta-cyclodextrin, 10-15 mg of dipyridamole and 8-10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and white blood cell morphological deformation, accurately identifies in white blood cell five classification, and has a classification accuracy as high as 98%, and is suitable for veterinary clinical hematology examination and animal disease monitoring.

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

The invention discloses an application of a TBOA analogue in preparation of a kit for testing platelet stress self-regulating force, and the platelet stress self-regulating force is reflected by the aggregation degree of platelets after being intervened by the TBOA analogue. The application focuses on a new mechanism of platelet activation, that is, when platelets are stimulated by activators such as thrombin, normal reactions of activation and aggregation are driven and maintained by adjusting uptake of glutamic acid by EAATs. Due to the clear action mechanism, the application can provide indexes and methods with higher specificity in diagnosis, treatment and prognosis evaluation of thrombotic diseases, and the pertinence is extremely high. According to the application, the influence of the TBOA analogue on the platelet aggregation degree is utilized to test the stress self-regulating force of the platelet, and new clinical application of the TBOA analogue is developed.

The present application relates to a kind of preservative solution for prolonging the in vitro storage period of platelet and its preparation method, containing baicalin 4.50~6.00g, baicalein 3.00~3.40g, sodium citrate 1.50~2.00g, citric acid 0.20~0.50g, glucose 7.90~8.50g per liter of preservative solution, and the remaining component is distilled water.The preservative solution of the present application adds a certain proportion of baicalin and baicalein, and the composition has a synergistic effect on inhibiting platelet activation, protection and inhibition of platelet aggregation, can prolong the in vitro platelet normal temperature storage time, and the normal temperature storage time can reach 16d.

This disclosure provides an antibody constructs that specifically bind CD9 with high affinity. These antibody constructs include a set of novel heavy chain and light chain complementarity determining regions (CDRs) sequences, optionally humanized variable regions, and engineered Fc region of the heavy chain constant region in order to eliminate undesirable platelet activation. The present invention also provides methods for diagnosing and treating conditions including cancer characterized by the aberrant expression of CD9 in the pertinent tissue and cells through the use of these anti-CD9 antibody constructs.

The invention relates to the technical field of medical examination and analysis, in particular to a platelet activation marker detection method which at least comprises the following steps: mixing a sample solution, a TXB2 isotope internal standard solution and a precipitator, and carrying out vortex treatment and centrifugal treatment to obtain a serum sample; a serum sample is subjected to LC-MS / MS testing, the content of thromboxane B2 in the sample is determined on the basis of a standard curve, quantitative detection of the content of TXB2 in serum is achieved by optimizing pretreatment and LC-MS / MS (liquid chromatography-tandem mass spectrometry) parameter conditions, and compared with a traditional ELISA method, the sensitivity is higher, the accuracy is higher, the result reproducibility is good, the method is more stable and reliable, and the method is suitable for large-scale popularization and application. Popularization and implementation are easy.

The invention belongs to the technical field of chemical synthesis of medicines, and particularly relates to a preparation process of azelastine hydrochloride, which comprises four steps of condensation reduction, hydrochloric acid hydrolysis, cyclization and hydrochloric acid salification. According to the method, the reaction efficiency, the product yield and the purity are improved, the production cost and the operation difficulty are reduced, and a stable, cost-controllable and repeatable preparation process is formed. The prepared azelastine hydrochloride is a long-acting anti-allergic drug, has dual effects of resisting histamine and inflammation, has high affinity to a receptor, effectively blocks histamine release of mast cells and basic granulocytes, has wide pharmacological effects on leukotriene, kinin, platelet activating factors and other inflammatory chemical mediators, and can be used for preparing an anti-allergic drug. Therefore, azelastine can effectively relieve typical symptoms of allergic conjunctivitis, such as pruritus, conjunctival congestion, lacrimation, conjunctival edema and the like.

Multivalent anti-platelet glycoprotein I(b)alpha antibodies can cause severe side effects. The present disclosure provides humanized antibodies specifically recognizing glycoprotein I(b)alpha and lacking a Fc portion, therefore Bleeding Time do not interact with Fc receptor. The humanized antibodies are capable of preventing platelet activation and aggregation, and reducing thrombus size / growth and prevent vessel occlusion. They can be also very useful to decrease platelet-tumor cell interaction and decrease tumor metastasis. At therapeutic doses, the humanized antibodies lack the ability to induce platelet activation, induce thrombocytopenia; and / or prolong bleeding time.

The invention belongs to the technical field of medicine, particularly relates to application of mGluR5 agonist CHPG in preparation of antithrombotic drugs, and proves that the mGluR5 agonist CHPG has an antithrombotic effect for the first time through platelet function detection, activation index analysis, a FeCl3 induced mouse artery injury model and protein phosphorylation detection. Researches show that the mGluR5 agonist CHPG significantly reduces the risk of thrombosis by inhibiting platelet activation, and has an antithrombotic application potential.

In illustrative embodiments, methods and systems for increasing blood coagulation potential in a subject and / or triggering a higher platelet activation rate in the subject via ear nerve stimulation include contacting the subject's skin with one or more therapeutic electrodes, each electrode is positioned in a respective region of a neural structure of an ear temporal nerve (ATN), a neural structure connected to the ATN, a neural structure of an ear branch (ABVN) of a vagus nerve, or a neural structure connected to the ABVN; one or more stimulation patterns are applied to the electrode.

This invention relates to an antibody or antigen-binding fragment of phosphorylated VASP-Ser 239 protein and its applications. The antibody comprises specific light and heavy chain variable region complementarity-determining region (CDR) sequences or amino acid sequences having at least 80% sequence identity with them. The invention also provides isolated polynucleotides encoding the antibody, expression vectors, recombinant cells, and methods for preparing the antibody. The antibody and its derivatives of this invention can efficiently and specifically detect phosphorylated VASP-Ser 239 protein in human whole blood or platelet cells, and are suitable for monitoring the inhibitory effect of platelet ADP receptor (P2Y12) antagonists (such as clopidogrel) on platelet activation, clarifying clopidogrel resistance, and guiding rational clinical drug use. This invention solves the current shortage of antibody raw materials and kits for related detection projects on the market.

This invention relates to the fields of biomedical engineering and regenerative medicine, and particularly to a plasma matrix composite membrane activated by autologous keratinized epithelial tissue fragments, its preparation method, and its applications. The composite membrane is obtained by mixing autologous keratinized epithelial tissue fragments with a liquid autologous plasma matrix in a specific ratio, utilizing tissue factors on the surface of the tissue fragments to trigger platelet activation, spontaneously forming a gel, and then pressing it into a membrane. This invention is the first to utilize the biointerface of autologous keratinized epithelial tissue fragments to activate platelets, eliminating the need for exogenous thrombin and achieving completely autologous in-situ gelation. The composite membrane formed after pressing possesses excellent mechanical properties and barrier function, and can be prepared in a single operation in the operating room without the need for in vitro cell culture. The composite membrane of this invention is used for oral soft tissue augmentation, such as widening of keratinized gingiva and alveolar ridge soft tissue augmentation, and has advantages such as no donor site damage, high biosafety, and ease of operation.

A series of sofalcone derivatives having the effect of inhibiting platelet aggregation and antithrombotic effect are disclosed. These sofalcone derivatives are antagonists of TxA2 receptor and have the effect of inhibiting platelet activation and aggregation without causing bleeding. In addition, a preparing method of the sofalcone derivatives and a method for preventing or treating thrombotic diseases or inhibiting platelet aggregation by administrating the sofalcone derivatives are also disclosed.

This invention discloses a platelet-rich plasma (PRP) preparation device, its preparation method, and its applications. The device comprises integrated sterile components for the entire process of blood collection, centrifugation, transfer, and recombination. Through an optimized secondary centrifugation process, it can stably and efficiently separate and enrich platelets from autologous whole blood, thereby preparing PRP that meets clinical requirements. The device features a rationally designed component structure and a standardized and simple operating procedure, effectively controlling unnecessary platelet activation during the preparation process and ensuring the bioactivity and release potential of growth factors in the PRP. Experimental results show that the growth factor enrichment efficiency and platelet activation level of the PRP obtained using this device are comparable to mainstream commercially available products, with superior ease of operation and standardization. This product provides a reliable and efficient PRP preparation tool for clinical use, particularly suitable for adjunctive treatment of trauma repair such as fracture surgery.

A container, e.g., a bag, for processing whole blood or a whole blood component and a system for processing whole blood or a whole blood component including the container. The container includes a body and an interior chamber. The body has a bulk portion and a surface portion defining an interior surface of the body. The bulk portion of the body is formed from a polymeric composition comprising a thermoplastic polymer. The surface portion of the body includes a biocompatible material that reduces platelet activation, platelet aggregation, or adhesion of platelets to the interior surface of the body. The interior chamber is at least partially defined by the interior surface of the body.

The application belongs to the field of medical biotechnology, and particularly relates to a method for in-vitro ADP stimulation determination of platelet activation and application. The method provided by the application comprises: S1, adding buffer solution, ADP solution and anticoagulant whole blood sample into a homologous control tube and a to-be-detected tube respectively; S2, placing the homologous control tube and the to-be-detected tube at 18-28 DEG C for 5-30 min for stimulation; the final concentration of the ADP solution in the step S1 is 5-160 micromol / L; and the addition amount of the anticoagulant whole blood sample is 5-10 microliters. The method provided by the application is more direct and simple to operate, and only needs to be completed at normal temperature. After the stimulation is completed, the antibody reagent is directly added without the need of taking a flow tube for secondary dispensing and adding the antibody reagent. In addition, the sample amount of the method provided by the application is significantly reduced, the burden of patients is reduced, the ADP amount is greatly reduced, the reagent amount is saved, the collection time is significantly shortened, and the detection efficiency is greatly improved.

The application discloses an anti-platelet GPIb-IX antibody and application thereof, and belongs to the technical field of biological medicines. The application selects the starting signal protein GPIb-IX of arterial thrombosis as a target, and prepares an anti-human GPIb-IX humanized antibody. Specifically, human platelets are used as antigens to immunize mice, and a mouse-derived anti-human GPIb-IX antibody is obtained through screening and preparation, a humanized anti-GPIb-IX antibody ATHA is constructed by mutating a human-derived sequence, the heavy chain variable region of the ATHA comprises a VH-CDR3 shown in SEQ ID NO. 1, and the light chain variable region comprises a VL-CDR3 shown in SEQ ID NO. 2. The Fab segment of the ATHA can effectively inhibit platelet activation mediated by the GPIb-IX receptor, inhibit thrombosis in the body without accompanying side effects such as platelet reduction and bleeding, and has the characteristics of high specificity, good safety and small side effects. Meanwhile, the ATHA can remove platelets. Therefore, the ATHA-Fab has clinical value as a new anti-thrombotic drug, and can be used for treating diseases related to arterial thrombosis. The ATHA can remove platelets, and can be used for treating diseases with increased platelet quantity or removing platelets in the body.

The invention discloses a novel application of harmine in preparation of thrombolytic drugs. The research shows that harmine can effectively dissolve formed thrombus and relieve vasculopathy, and has the function of protecting blood vessels. After thrombus is formed, harmine is given, and thrombolysis treatment can be achieved through the following steps that the blood flow speed and the blood flow volume of the thrombus part are rapidly recovered; platelet activation and endothelial cell injury are obviously inhibited; and oxidative stress is eliminated. The blood flow disorder caused by thrombus can be quickly improved; formed thrombus is effectively dissolved; the normal vasomotor function is maintained; the physiological hemostasis function is not interfered. The harmine is remarkable in thrombolysis effect and quick in action; the curative effect is lasting; the safety is high and the bleeding risk is low. The invention provides a brand new drug choice for treating thrombotic diseases, and has important clinical application value.

The invention discloses application of a platelet activating factor in preparation of a medicine for treating endometrial cancer. Cell experiments and animal in-vivo experiments prove that the platelet activating factor can effectively inhibit proliferation of the endometrial cancer and inhibit in-vivo growth of the endometrial cancer, the targeted binding effect of PAF and ATF3 is clarified, a new method is provided for treatment of the endometrial cancer, and the platelet activating factor is expected to be applied to preparation of drugs for inhibiting proliferation of the endometrial cancer and has a wide application prospect. The invention has important significance for clinical treatment of endometrial cancer.